Myelodysplastic Syndromes
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndromes.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-05-14Clinical Trial Update: Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome [Phase 1, Phase 2]
This update reports completion of a Phase 1/2 study evaluating the glutaminase inhibitor Telaglenastat (CB-839) in combination with azacitid…
-
CLINICAL_TRIALS research · 2024-05-14Clinical Trial Update: Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT [Phase 3]
Phase 3 randomized trial evaluating oral azacitidine versus placebo as maintenance therapy after allogeneic stem cell transplantation in pat…
-
CLINICAL_TRIALS trial_result · 2024-05-07Clinical Trial Update: Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) [Phase 2]
This Phase 2 clinical trial update reports on conditioning with benadamustine, fludarabine, and busulfan (FluBuBe) for recipients of haploid…
-
CLINICAL_TRIALS trial_result · 2024-05-06Clinical Trial Update: Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients [Phase 2]
Phase 2 trial evaluated the efficacy and safety of canakinumab for treating anemia in patients with lower-risk myelodysplastic syndromes. Th…
-
CLINICAL_TRIALS trial_result · 2024-05-03Clinical Trial Update: Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers [Phase 2]
A Phase 2 clinical trial update on haploidentical stem cell transplantation for multiple hematologic cancers, with the study status reported…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-05-02Clinical Trial Update: Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes [Phase 1]
Phase 1 trial update (completed) on the combination of vosaroxin and azacitidine in myelodysplastic syndromes.
-
CLINICAL_TRIALS research · 2024-05-01Clinical Trial Update: Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML [Phase 1, Phase 2]
A Phase 1/2 clinical trial assessing adding venetoclax to FLAMSA/treosulfan conditioning for allogeneic stem cell transplantation in patient…
-
CLINICAL_TRIALS withdrawal · 2024-04-29Clinical Trial Update: High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD [Phase 1, Phase 2]
The trial update indicates that the Phase 1/2 study of high-dose post-transplant cyclophosphamide, bortezomib, and sitagliptin for preventio…
-
CLINICAL_TRIALS trial_result · 2024-04-22Clinical Trial Update: Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation [EARLY_Phase 1]
A phase 1 pilot trial evaluating pembrolizumab for relapse after allogeneic stem cell transplantation in patients with classical Hodgkin lym…
-
CLINICAL_TRIALS trial_result · 2024-04-15Clinical Trial Update: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [Phase 1, Phase 2]
A Phase 1/2 trial evaluating TJ011133 as monotherapy and in combination with azacitidine in AML or MDS has completed.
-
FDA approval · 2024-03-29FDA Approved: AZACITIDINE — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for azacitidine from Accord Healthcare Inc., enabling continued regulatory authorization of the gene…
-
CLINICAL_TRIALS trial_result · 2024-03-27Clinical Trial Update: A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations [Phase 1, Phase 2]
A Phase Ib/II study assessing the safety and tolerability of vitamin C in patients with intermediate- or high-risk myelodysplastic syndromes…
-
CLINICAL_TRIALS trial_result · 2024-03-26Clinical Trial Update: APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant [Phase 2]
Phase 2 clinical trial update reporting results for APR-246 in combination with azacitidine for TP53-mutated acute myeloid leukemia or myelo…
-
CLINICAL_TRIALS trial_result · 2024-03-26Clinical Trial Update: RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT [Phase 2]
Phase 2 trial evaluating a reduced-intensity conditioning regimen for elderly or high-comorbidity patients undergoing haploidentical hematop…
-
CLINICAL_TRIALS trial_result · 2024-03-21Clinical Trial Update: Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS [Phase 2]
Phase 2 clinical trial evaluating allogeneic hematopoietic stem cell transplantation with FBM conditioning for myelodysplastic syndrome with…
-
CLINICAL_TRIALS trial_result · 2024-03-21Clinical Trial Update: Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating a combination of sirolimus, abatacept, and mycophenolate mofetil to prevent aGraft-versus-Host Disease…
-
CLINICAL_TRIALS trial_result · 2024-03-21Clinical Trial Update: Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) [Phase 3]
Phase 3 trial evaluating magrolimab plus azacitidine versus azacitidine plus placebo in untreated myelodysplastic syndrome (MDS) patients wa…
-
CLINICAL_TRIALS trial_result · 2024-03-19Clinical Trial Update: NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) [Phase 1, Phase 2]
Phase 1/2 clinical trial update on NK donor lymphocyte infusion following HLA-haploidentical HSCT; study status completed.
-
CLINICAL_TRIALS trial_result · 2024-02-23Clinical Trial Update: Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q [Phase 2]
Phase 2 study assessing safety of lenalidomide and markers for disease progression in IPSS low- or intermediate-1 risk myelodysplastic syndr…
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS [Phase 1, Phase 2]
Clinical trial update on APG-115 alone or with azacitidine in patients with AML, CMML, or MDS across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy [Phase 2]
Phase 2 clinical trial update for MGTA-456 in high-risk hematologic malignancies; results were posted in 2024 and the study is currently act…
-
CLINICAL_TRIALS trial_result · 2024-01-23Clinical Trial Update: A Study of TQB3454 Tablets in Patients With Blood Tumors [Phase 1, Phase 2]
Clinical trial update for TQB3454 tablets in blood tumors (Phase 1/2) involving Acute Myeloid Leukemia and Myelodysplastic Syndromes.
-
EMA approval · 2024-01-10EMA Authorised: Azacitidine betapharm (azacitidine) — betapharm Arzneimittel GmbH
Azacitidine betapharm (azacitidine) has been authorised in the EU for use in myelodysplastic syndromes and various leukemias, with betapharm…
-
CLINICAL_TRIALS trial_result · 2023-12-11Clinical Trial Update: Empirical Versus Preemptive Antifungal Therapy [Phase 3]
Phase 3 trial comparing empirical versus preemptive antifungal therapy in patients with fungal infection and leukemia/myelodysplastic syndro…
-
CLINICAL_TRIALS withdrawal · 2023-11-24Clinical Trial Update: Transfusion Effects in Myelodysplastic Patients: Limiting Exposure [Phase 4]
Phase 4 trial on transfusion effects in myelodysplastic syndromes was withdrawn.